本次医保谈判结果有助于本公司进一步提高轩悦宁®在患者中的可负担性和可及性，有利于进一步推动 该药物的市场推广、提升销售规模，对本公司的长期经营发展具有积极影响。本公司将积极配合推进医 保政策落地，持续推进医院准入工作、拓展核心市场及扩大市场的覆盖，以期不断提升患者的用药可及 性。 智通财经获悉，轩竹生物-B(02575)涨近3%，截至发稿，涨1.98%，报66.95港元，成交额1519.53万港 元。 本文源自：智通财经网 消息面上，12月8日，轩竹生物-B发布公告，本公司自主研发的创新药吡洛西利片(商品名：轩悦宁®)首 次纳入《国家基本医疗保险、生育保险和工伤保险药品目录( 2025年 )》(2025国家基本医保目录)。 2025国家基本医保目录将于2026年1月1日正式执行。 ...

Group 1 - The core point of the article is that Xuan Bamboo Biotech-B (02575) has seen a stock price increase following the announcement that its innovative drug, Pirlosil, has been included in the 2025 National Basic Medical Insurance Directory [1] - As of the report, the stock price rose by 1.98% to HKD 66.95, with a trading volume of HKD 15.1953 million [1] - The inclusion of Pirlosil in the insurance directory is expected to enhance its affordability and accessibility for patients, which will positively impact the drug's market promotion and sales growth [1] Group 2 - The 2025 National Basic Medical Insurance Directory will officially take effect on January 1, 2026 [1] - The company plans to actively support the implementation of the insurance policy, continue hospital access efforts, and expand its core market to improve patient access to medication [1] - This development is viewed as beneficial for the company's long-term operational growth [1]

Core Viewpoint - Xuan Bamboo Biotech-B (02575) shares rose nearly 3%, currently up 1.98% at HKD 66.95, with a trading volume of HKD 15.1953 million following the announcement of its innovative drug, Pirlosil, being included in the 2025 National Basic Medical Insurance Directory [1] Group 1 - The innovative drug Pirlosil (brand name: Xuan Yue Ning) has been included in the 2025 National Basic Medical Insurance Directory, which will be implemented on January 1, 2026 [1] - The inclusion in the insurance directory is expected to enhance the affordability and accessibility of Xuan Yue Ning for patients, thereby promoting market expansion and increasing sales scale [1] - The company plans to actively support the implementation of the insurance policy, continue to advance hospital access, expand core markets, and increase market coverage to improve patient access to medication [1]

Major Events - GuoXia Technology (02655) plans to conduct an IPO from December 8 to December 11, offering 33.85 million H-shares and introducing cornerstone investors such as Huikai Hong Kong [1] - Basilea Pharmaceutica AG (02616) has its drug Pujihua® (Pralsetinib Capsules) included in the National Medical Insurance Directory for 2025 [1] - Four Seasons Pharmaceutical (00460) sees its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Shanghai Pharmaceuticals (02607) successfully negotiates and includes Amisulpride Orally Disintegrating Tablets in the National Medical Insurance Directory [1] - Hansoh Pharmaceutical (03692) has its innovative drug Amelotex® approved for two new indications in the updated 2025 National Medical Insurance Directory [1] - Xiansheng Pharmaceutical (02096) sees EnzeShu® and EnDu® included in the updated National Medical Insurance Drug List [1] - Hutchison China MediTech (00013) has its drug Tazverik® included in the first edition of the National Commercial Health Insurance Innovative Drug List [1] - XuanZhu Biotechnology (02575) has its innovative drug XuanYueNing® included in the National Basic Medical Insurance Drug List for the first time [1] - Yino Pharmaceutical (02591) has its H-shares included in the list of eligible securities for the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect [1] - China Metallurgical Group (01618) and its subsidiaries plan to sell non-core business assets for approximately 60.68 billion yuan, focusing on core businesses in metallurgical engineering, non-ferrous metals, and mining engineering [1] - Cambridge Technology (06166) intends to invest a total of 405 million yuan to acquire and subscribe for shares in the Yangzhong Happiness Home Venture Capital Partnership Fund [1] Operating Performance - Dongfeng Motor Group (00489) reports cumulative automobile sales of 1.697 million units in the first 11 months, a year-on-year decrease of approximately 0.3% [2] - New天绿色能源 (00956) achieves a cumulative power generation of 1,336.89 million MWh in the first 11 months, an increase of 8.04% year-on-year [2] - Longyuan Power (00916) reports a cumulative power generation of approximately 6,909.64 million MWh in the first 11 months, a year-on-year growth of 0.41% [2] - Baolong Real Estate (01238) records a total contract sales of approximately 6.666 billion yuan in the first 11 months, a year-on-year decline of 43.2% [2]

Core Insights - The recent adjustment of the National Medical Insurance Directory for 2025 has significantly benefited XuanZhu Biotech, marking a pivotal moment for its innovative drugs [1][2] - The inclusion of the CDK4/6 inhibitor Palbociclib and the renewal of the proton pump inhibitor Anaprazole in the insurance directory are crucial for the commercialization phase of these products [2][4] Product Developments - Palbociclib is the only approved single-agent treatment for HR+/HER2- breast cancer in China, with a projected market growth from 3 billion yuan in 2024 to 13 billion yuan by 2032, reflecting a compound annual growth rate of 20.2% [5][8] - Anaprazole, as the first self-developed PPI in China, has shown steady revenue growth, achieving approximately 30.1 million yuan and 17.9 million yuan in revenue for the fiscal years ending December 31, 2024, and June 30, 2025, respectively [10] Market Positioning - The successful inclusion of these drugs in the insurance directory enhances patient accessibility and aligns with the industry's trend towards addressing clinical needs and achieving scale [4][10] - XuanZhu Biotech's strategic focus on differentiated innovation and expanding its product pipeline positions it well against the backdrop of increasing competition in the innovative drug sector [12][13] Financial Performance - The company has demonstrated a robust capital structure, with over 20% of its shares held by external investment institutions, indicating strong recognition of its R&D capabilities [2] - The transition from a biotech phase reliant on financing to a biopharma phase capable of generating cash flow is evident as the company’s R&D expenditures decrease while revenue increases [22] Strategic Collaborations - XuanZhu Biotech's collaboration with Akamis Bio to introduce the injectable oncolytic virus therapy NG-350A highlights its commitment to expanding its innovative pipeline and enhancing its market presence [16] - The company is also advancing several first-in-class products, such as the HER2 dual-targeting ADC KM501 and the CD80 fusion protein KM602, which are currently in clinical trials [15] Market Trends - The innovative drug sector is experiencing a shift from a focus on pipeline scarcity to a demand for tangible commercialization results, with investors prioritizing companies that can efficiently convert R&D into marketable products [18][19] - XuanZhu Biotech's established sales teams and distribution networks in the oncology and digestive disease sectors provide a solid foundation for rapid product uptake [20] Long-term Outlook - The combination of immediate revenue growth from newly approved products and a long-term strategy focused on differentiated pipeline development positions XuanZhu Biotech favorably for future valuation increases [25] - The company's ability to balance short-term performance with long-term growth potential is expected to attract investor interest in the evolving landscape of the innovative drug market [23][24]

作为首款且唯一国内自主研发的质子泵抑制剂，安久卫于2023年6月在中国获批上市，用于治疗十二指 肠溃疡，并于2023年12月首次纳入国家基本医保药品目录。本次安久卫成功续约2025年国家基本医保药 品目录，将利于稳定市场销售，继续惠及更多患者人群，提升该产品在相关适应症上的渗透率，为安久 卫的长期增长注入动力。 轩竹生物-B(02575)发布公告，经过与中国国家医疗保障局(国家医保局)的简易医保续约，本公司自主研 发的创新药安奈拉唑钠肠溶片(商品名：安久卫)将继续获纳入自2026年1月1日起生效的新版《国家基本 医疗保险、生育保险和工伤保险药品目录(2025年)》(2025年国家基本医保药品目录)。 ...

智通财经APP讯，轩竹生物-B(02575)发布公告，经过与中国国家医疗保障局(国家医保局)的简易医保续 约，本公司自主研发的创新药安奈拉唑钠肠溶片(商品名：安久卫)将继续获纳入自2026年1月1日起生效 的新版《国家基本医疗保险、生育保险和工伤保险药品目录(2025年 )》(2025年国家基本医保药品目 录)。 作为首款且唯一国内自主研发的质子泵抑制剂，安久卫于2023年6月在中国获批上市，用于治疗十二指 肠溃疡，并于2023年12月首次纳入国家基本医保药品目录。本次安久卫成功续约2025年国家基本医保药 品目录，将利于稳定市场销售，继续惠及更多患者人群，提升该产品在相关适应症上的渗透率，为安久 卫的长期增长注入动力。 ...

作为首款且唯一国内自主研发的质子泵抑制剂，安久卫®于2026年6月在中国获批上市，用于治疗十二 指肠溃疡，并于2026年十二月首次纳入国家基本医保药品目录。本次安久卫®成功续约2025年国家基本 医保药品目录，将利于稳定市场销售，继续惠及更多患者人群，提升该产品在相关适应症上的渗透率， 为安久卫®的长期增长注入动力。 格隆汇12月8日丨轩竹生物-B(02575.HK)宣布，经过与中国国家医保局的简易医保续约，公司自主研发 的创新药安奈拉唑钠肠溶片(商品名：安久卫®)将继续获纳入自2026年1月1日起生效的新版《国家基本 医疗保险、生育保险和工伤保险药品目录(2025年)》。 ...

本次医保谈判结果有助于本公司进一步提高轩悦宁在患者中的可负担性和可及性，有利于进一步推动该 药物的市场推广、提升销售规模，对本公司的长期经营发展具有积极影响。本公司将积极配合推进医保 政策落地，持续推进医院准入工作、拓展核心市场及扩大市场的覆盖，以期不断提升患者的用药可及 性。 轩竹生物-B(02575)发布公告，本公司自主研发的创新药吡洛西利片(商品名：轩悦宁)首次纳入《国家基 本医疗保险、生育保险和工伤保险药品目录(2025年)》(2025国家基本医保目录)。2025国家基本医保目 录将于2026年1月1日正式执行。 ...

智通财经APP讯，轩竹生物-B(02575)发布公告，本公司自主研发的创新药吡洛西利片(商品名：轩悦宁) 首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录( 2025年 )》(2025国家基本医保目录)。 2025国家基本医保目录将于2026年1月1日正式执行。 本次医保谈判结果有助于本公司进一步提高轩悦宁在患者中的可负担性和可及性，有利于进一步推动该 药物的市场推广、提升销售规模，对本公司的长期经营发展具有积极影响。本公司将积极配合推进医保 政策落地，持续推进医院准入工作、拓展核心市场及扩大市场的覆盖，以期不断提升患者的用药可及 性。 ...